Biosynthesis of Macrolactam BE-14106 Involves Two Distinct PKS Systems and Amino Acid Processing Enzymes for Generation of the Aminoacyl Starter Unit  by Jørgensen, Hanne et al.
Chemistry & Biology
ArticleBiosynthesis of Macrolactam BE-14106 Involves
TwoDistinct PKSSystems andAminoAcid Processing
Enzymes for Generation of the Aminoacyl Starter Unit
Hanne Jørgensen,1 Kristin F. Degnes,2 Ha˚vard Sletta,2 Espen Fjærvik,1 Alexander Dikiy,1 Lars Herfindal,4 Per Bruheim,1
Geir Klinkenberg,2 Harald Bredholt,3 Gyrid Nyga˚rd,4 Stein O. Døskeland,4 Trond E. Ellingsen,2 and Sergey B. Zotchev1,*
1Department of Biotechnology, Norwegian University of Science and Technology, N-7491 Trondheim, Norway
2Department of Industrial Biotechnology, SINTEF Materials and Chemistry, SINTEF, N-7034 Trondheim, Norway
3Axellia AS, Harbitzaleen 3, 0275 Oslo, Norway
4Department of Biomedicine, University of Bergen, N-5009 Bergen, Norway
*Correspondence: sergey.zotchev@nt.ntnu.no
DOI 10.1016/j.chembiol.2009.09.014SUMMARY
BE-14106 is a macrocyclic lactam with an acyl side
chain previously identified in a marine-derived Strep-
tomyces sp. The gene cluster for BE-14106 biosyn-
thesis was cloned from a Streptomyces strain newly
isolated from marine sediments collected in the
Trondheimsfjord (Norway).Bioinformatics andexperi-
mental analyses of the genes in the cluster suggested
an unusual mechanism for assembly of the molecule.
Biosynthesis of the aminoacyl starter apparently
involves the concerted action of a distinct polyketide
synthase (PKS) system and several enzymes that
activate and process an amino acid. The resulting
starter unit is loaded onto a second PKS complex,
which completes the synthesis of the macrolactam
ring. Gene inactivation experiments, enzyme assays
with heterologously expressed proteins, and feeding
studies supported the proposed model for the biosyn-
thesis and provided new insights into the assembly of
macrolactams with acyl side chain.
INTRODUCTION
Macrocyclic lactams (macrolactams) have been shown to have
a wide range of activities, e.g., bactericidal (Zafriri et al., 1981),
antiviral (Naruse et al., 1991), cytotoxic (Futamura et al., 2008),
antifungal (Jakobi et al., 1996), and antiprotozoal (Jomon et al.,
1972). BE-14106 is a macrolactam antibiotic exhibiting antibac-
terial, antifungal, and anticancer activity first described in 1992,
when the compound was isolated from a Streptomyces strain
designated as S. spheroids A14106 (Kojiri et al., 1992). A second
Streptomyces producer of BE-14106 and 8-deoxy BE-14106
was described some years later (Takahashi et al., 1997). In
both cases activity against cancer cell lines was shown, but
the mechanism behind BE-14106’s anticancer properties has
not been elucidated. The structure of BE-14106 is shown in
Figure 1 along with similar small-ring macrolactams.
Currently, there are no macrolactams in use as antineoplastic
agents, but a derivative of the ansamycin antibiotic geldanamy-Chemistry & Biology 16, 1109cin has completed phase I clinical trials (Nowakowski et al.,
2006) and several more have been described that have anti-
cancer activity. Vicenistatin was active against xenographed
models of certain human colon cancers (Shindo et al., 1993),
hitachimycin/stubomycinand itsderivativeshad inhibitoryactivity
against murine tumors (Umezawa et al., 1981; Komiyama et al.,
1982; Shibata et al., 1988, 1989a, 1989b), aureoverticillactam
was found to have cytotoxic activity against several tumor cell
lines (Mitchell et al., 2004), and leinamycin and its derivatives
have shown antitumor activity against several types of tumors
and cancer cell lines (Hara et al., 1989a, 1989b; Kanda et al.,
1998, 1999, 2003; Bassett et al., 2004).
In the biosynthetic pathway for ansamycins (e.g., Rascher
et al., 2003; Yu et al., 2002) 3-amino-5-hydroxybenzoic acid
usually represents the starter unit, while amino acids or amino
acid derivatives are used as starters for the synthesis of vicenis-
tatin (Ogasawara et al., 2004), leinamycin (Cheng et al., 2003),
and salinilactam (Udwary et al., 2007). The biosynthetic gene
clusters for macrolactams often contain both polyketide syn-
thases (PKS) and enzymes similar to nonribosomal peptide
synthetase (NRPS) domains, and the biosyntheses appear to
involve a cooperative action of these two types of enzyme
systems. Thebiosynthesis of leinamycin startswith the activation
of D-alanine by a discrete adenylation (A) domain and loading on
a discrete peptidyl carrier protein (PCP) domain (Tang et al.,
2007). The discrete A and PCP domains are thought to represent
the loading module for the biosynthesis and chain elongation
proceeds through one additional NRPS module and six PKS
modules (Cheng et al., 2003). None of the PKS modules contain
the usual acyltransferase (AT) domain for activation and loading
of thebuildingblocksandmalonyl-CoAunits are insteadsupplied
in trans by a discrete acyltransferase. The PKS enzymes involved
in the biosynthesis of vicenistatin are more conventional in the
sense that all extender modules include the core b-ketosynthase
(KS), AT, and acyl carrier protein (ACP) domains (Ogasawara
et al., 2004). The loading module is represented by a single
ACP domain, which presumably accepts the amino acid-derived
starter 3-methylaspartate. The vicenistatin biosynthetic gene
cluster encodes several enzymes assumed to be involved in
synthesizing the starter, and Ogasawara et al. (2004) proposed
several possible pathways for the generation of 3-methylaspar-
tate from glutamate. In analogy to the vicenistatin biosynthesis,–1121, October 30, 2009 ª2009 Elsevier Ltd All rights reserved 1109
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Small-Ring Macrolactam with Acyl Side Chainsalinilactam is synthesized by a PKS system using an amino acid
as the starter. A lysine derivative was assumed to represent the
starter; however, the details of the starter unit synthesis have
not been elucidated (Udwary et al., 2007). Judging from the
biosynthesis of these different macrolactams, nature has appar-
ently generated several possible pathways for producing such
compounds.
Figure 1. Structures of BE-14106 and Similar Small-Ring Macrolac-
tams1110 Chemistry & Biology 16, 1109–1121, October 30, 2009 ª2009 EIn this study we report the isolation of a BE-14106-producing
Streptomyces strain from marine sediment, confirm and extend
the knowledge about the antifungal and cytotoxic activity of BE-
14106, describe the sequencing and analysis of the BE-14106
biosyntheticgenecluster, andproposeamodel for itsbiosynthesis.
RESULTS
Isolation of a New BE-14106 Producer
from Marine Sediment
Streptomyces sp. DSM 21069 was isolated as a part of a
screening effort aimed at identifying new antifungal compounds
produced by marine actinomycetes. The screening included
spectroscopic analysis of DMSO extracts coupled to an assay
for activity against Candida strains (see Experimental Proce-
dures). The screening resulted in the identification of a group of
30 actinomycete isolates, including Streptomyces sp. DSM
21069, which could be assumed to produce non-polyene anti-
fungal compounds based on the UV profile (lack of characteristic
polyene absorption peaks) and the biological activity (compa-
rable inhibition of both polyene-resistant and -sensitive strain).
DMSO extracts from Streptomyces sp. DSM 21069 and other
isolates selected from this group were subjected to liquid chro-
matography fractionation, identification of bioactive fractions,
and LC-MS-TOF analysis as described in Experimental Proce-
dures. In LC-MS analysis of bioactive fractions from six extracts,
significant peaks with a molecular mass corresponding to the
macrolactam BE-14106 were identified. The molecular mass
observed in the LC-MS-TOF analysis was within 1 ppm of the
molecular mass given in Database of Natural Products (DNP;
accurate mass 423.277344) (see Figure S1 available online). In
addition, the DAD profiles of these extracts correlated well with
the information given in DNP about the UV absorbance spectra
of BE-14106. Although BE-14106 is apparently a tetraene (Fig-
ure 1), its UV profile does not have a polyene-characteristic three
peak spectrum (data not shown), thus explaining why these
extracts were not disqualified during the screening for non-poly-
ene antifungals. The six isolates found to produce the BE-14106-
like compound were morphologically similar and taxonomic
characterization by analysis of 16S rDNA from three out of the
six strains showed that they presumably represented replicates
of the same strain (data not shown). Streptomyces sp. DSM
21069 was chosen for further work since it provided the highest
yield of presumed BE-14106 (1 g/liter in shake flasks).
The BE-14106-like compound was extracted to produce a
crude product (see Experimental Procedures) and purified to
99% purity by preparative HPLC. The biological assays using
the yeast strains Candida albicans and Candida glabrata (see
Experimental Procedures) determined that the lowest concen-
trations resulting in >50% inhibition of the two strains (IC50)
were 7.1 and 3.5 mM, respectively (Table 1).
The purified compound was further tested against human
Jurkat-T lymphoma cells and normal rat kidney epithelial cells
(NRK). The IC50 value for the compound based on theWST signal
(metabolic activity) was 4.5 and 7.0 mM, respectively (Table 1),
i.e., its potency was similar to that against the fungal strains.
Importantly, the LC50 value based on the morphologically
evident apoptosis was similar (data not shown), indicating thatlsevier Ltd All rights reserved
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Small-Ring Macrolactam with Acyl Side Chainthe presumed BE-14106 acted by inducing apoptotic cell death
rather than by merely arresting cell growth.
The identity of the purified compound as BE-14106 was then
confirmed by NMR spectroscopy. The chemical shifts observed
for both the 1H and 13C nuclei (Table S1) were almost identical to
those earlier reported for BE-14106 (Kojiri et al., 1992). Since
chemical shift is an extremely sensitive indicator of the nucleus
environment, and thus of the structure of a molecule, the NMR
results unambiguously confirmed that the compound isolated
was authentic BE-14106.
Cloning of the BE-14106 Biosynthetic Gene Cluster
To elucidate the pathway for BE-14106 biosynthesis, the corre-
sponding biosynthetic gene cluster was subsequently cloned
from Streptomyces sp. DSM 21069 (see Supplemental Experi-
mental Procedures for details). In essence, DNA fragments
encoding parts of KS domains of modular PKS were PCR ampli-
fied, sequenced, and analyzed. This resulted in identification of
one fragment encoding part of a KS domain with 73% identity
to the VinP1 PKS involved in the biosynthesis of themacrolactam
vicenistatin in Streptomyces halstedii (Ogasawara et al., 2004).
To ensure that this DNA fragment belonged to the BE-14106
biosynthetic gene cluster, a gene inactivation experiment using
this fragment was performed (see Supplemental Experimental
Procedures), which resulted in complete abrogation of BE-
14106 biosynthesis. Using this fragment, and subsequent chro-
mosome ‘‘walking,’’ four overlapping cosmids were identified in
the DSM 21069 genomic library. End sequencing of the cosmids
suggested that they encompassed the complete BE-14106
biosynthetic gene cluster. Next, KS-encoding DNA fragments
were amplified from cosmids 2 and 3 using one cosmid primer
and one degenerate primer for the KS domain. A 1.1 kb fragment
was obtained for cosmid 2 and a 3.7 kb fragment for cosmid 3.
Both fragments were cloned, sequenced, and used to construct
gene inactivation vectors. The vectors were transferred into
Streptomyces sp. DSM 21069 by conjugation and the transcon-
jugants obtainedwere analyzed for production of BE-14106. This
analysis demonstrated almost complete abrogation of BE-14106
biosynthesis when the 1.1 kb fragment was used, and >99%
reduction of yield for the 3.7 kb fragment. Based on these results
it was concluded that cosmids 1–4 contained the BE-14106
biosynthetic cluster and the four cosmids were fully sequenced.
Gene Organization within and around the BE-14106
Biosynthetic Gene Cluster
The genomic region represented by the sequenced cosmids
encompasses 85,059 bp and contains, according to the
Table 1. Biological Activity of BE-14106
Cell Line/Strain (ATCC no.) Origin IC50
a (mM)
Jurkat-T (TIB-152) Human T cell lymphoma 4.5 ± 1.1
NRK (CRL-6509) NRK 7.0 ± 1.4
C. albicans (CCUG3943) Clinical isolate 7.1
C. glabrata (CCUG3942) Clinical isolate 3.5
a The IC50 values for cell lineswasdeterminedby theWST-1 assay and the
IC50 values forCandida strains were determined as the lowest concentra-
tion resulting in >50% reduction in growth (optical density at 660 nm) as
compared to reference samples containing the solvent (DMSO).Chemistry & Biology 16, 1109FramePlot (Ishikawa and Hotta, 1999) and BLAST analyses, 27
complete and 1 incomplete open reading frames (orfs; Figure 2).
Results of the bioinformatics analysis of predicted gene prod-
ucts with proposed functions are presented in Table 2. Homo-
logs from the biosynthetic gene clusters of the structurally similar
macrolactams vicenistatin and salinilactam have also been
included in the table. Initially, based on the structural features
of BE-14106 and general knowledge of the organization of
secondary metabolite biosynthetic gene clusters, 21 of the iden-
tified orfs were suggested to be involved in the biosynthesis of
this compound. The PKS genes in the cluster are represented
by the genes becA–G, which are organized in four subclusters
(Figure 2). Interestingly, both becA and becC are truncated at
30 and 50 ends, respectively, thus encoding truncated PKS
proteins. Although this feature has been described for several
other secondary metabolite gene clusters (e.g., Duitman et al.,
1999; Kopp et al., 2005; Piel et al., 2004; Silakowski et al.,
2001), we could not exclude that rearrangements might have
occurred during cloning or there might have been mistakes in
the assembly of the sequences. We therefore decided to verify
the organization of the becA-becC region in the chromosome
of Streptomyces sp. DSM 21069. For this purpose, a 4.4 kb
DNA fragment encompassing the 30 end of becA and the 50
end of becB was amplified by PCR and subjected to restriction
analysis. Data obtained (data not shown) were fully consistent
with the proposed DNA sequence of this region, thus ruling out
the possibility of rearrangements during cloning or mistakes in
the assembly.
Besides the PKS genes presumably involved in the synthesis
of the macrolactam ring and the C20-C25 acyl side chain (see
below), the genes predicted to be involved in the activation
and modification of the nitrogen-donating amino acid have
been identified. These genes, becJ, S, L, and K, were localized
at the center of the gene cluster and encode an AMP-dependent
acyl-CoA synthetase/ligase, a discrete PCP, a discrete NRPS
adenylation domain, and a discrete acyltransferase, respectively
(see Discussion).
Genes becH and becM presumably encode transcriptional
regulators that control the biosynthesis of BE-14106. BecH
was homologous of several LuxR-type transcriptional regulators,
e.g., GdmRI from the geldanamycin biosynthesis in Strepto-
myces hygroscopius (He et al., 2008) and NysRI from the nystatin
biosynthesis in Streptomyces noursei (Sekurova et al., 2004).
BecM showed homology to TetR-type transcriptional regulators
and the closest matchwas Strop_2766, whose gene sequence is
located close to the salinilactam biosynthetic gene cluster in
Salinispora tropica.
In addition to the aforementioned becK, a second putative
acyltransferase, orf10, located at the right flank of the cluster
was identified. orf10 encodes a homolog of PlsC-type phospho-
lipids/glycerol acyltransferases and could potentially have a role
in the biosynthesis of BE-14106. A gene inactivation experiment
affecting orf10 had, however, no effect on the BE-14106 produc-
tion (data not shown).
A gene encoding thioesterase type II (TEII), becQ, was identi-
fied upstream of the orf10 gene. Such thioesterases are often
associated with PKS and NRPS clusters and are thought to be
responsible for deblocking ACP/PCP domains that have been
misacylated (Kim et al., 2002; Schwarzer et al., 2002). TEIIs–1121, October 30, 2009 ª2009 Elsevier Ltd All rights reserved 1111
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Small-Ring Macrolactam with Acyl Side ChainFigure 2. Organization of the BE-14106 Biosynthetic Gene Cluster in Streptomyces sp. DSM 21069
PKS, green; genes presumed to be involved in modification of aminoacyl starter, red; regulators/efflux pump, blue; post-PKSmodification, yellow; not involved in
biosynthesis of BE-14106, gray. Coverage of the four sequenced cosmids is shown.have alsobeen ascribed a role in themodification of starter amino
acid units. In the chloroeremomycin and the nikkomycin biosyn-
thesis, TEIIs have been suggested to be responsible for releasing
the amino acid from the PCP domain after initial modification
(Chen et al., 2001). BecQ is also homologous to Strop_2763,
a putative thioesterase whose corresponding gene is located
quite close to the salinilactam biosynthetic gene cluster in Sal.
tropica.
The becO gene encoding a putative P450 monooxygenase
was tentatively assigned the role of a C-8 hydroxylase respon-
sible for the modification of the macrolactam ring.
The gene cluster contains one gene, becN, whose translation
product might be involved in the BE-14106 transport or resis-
tance mechanism. BecN resembles major facilitator super-
family-type efflux pumps and might be responsible for the efflux
of BE-14106 from the cell. BecNwas homologous to the product
of Strop_2765, a gene located in close proximity to the salinilac-
tam cluster in Sal. tropica.
Several genes whose products could not be assigned specific
functions in the BE-14106 biosynthesis were found in the cluster.
The translation product of becT is a putative protein of 95 amino
acids with only poor homology to several hypothetical proteins.
Based on the sequence analysis alone it was not possible to
suggest a role for BecT in the BE-14106 biosynthesis. Three
genes with unclear function, becI, becP, and becU, were found
to encode a putative glycine oxidase/FAD-dependent oxidore-
ductase, L-amino acid amidase/proline iminopeptidase, and
NRPS accessory protein, respectively. BecI was homologous
to putative glycine oxidases from potential thiamin biosynthetic
gene clusters in several Streptomyces genome sequences, but
no becI homologs were found in the other characterized macro-
lactam biosynthesis gene clusters. BecP showed the highest
homology to VinJ and Strop_2777 from the vicenistatin and sal-
inilactam biosynthesis pathways, respectively (Ogasawara et al.,
2004; Udwary et al., 2007). Both VinJ and Strop_2777 were
thought to represent proline-specific peptidases, but functional
roles in the biosynthesis were not assigned for them. BecU
showed homology to several hypothetical proteins for which
the corresponding genes were all located within clusters con-
taining both NRPS- and PKS-encoding genes. The highest
homology was to hypothetical protein SAV_606 from the
genome sequence of Streptomyces avermitilis MA-4680, but
the product presumably synthesized by the enzymes encoded
by the tentative biosynthetic gene cluster has not been charac-
terized (O˜mura et al., 2001).1112 Chemistry & Biology 16, 1109–1121, October 30, 2009 ª2009 EOrfs1–3 and 6–9, located at the left and right flanks of the gene
cluster, do not seem to have any roles in the BE-14106 biosyn-
thesis, judging from the analysis of their translation products
(Table 2).
Organization and Functional Assignments
of the PKS Proteins
To assign specific roles for the seven PKS genes in the biosyn-
thesis of BE-14106, their translation products were analyzed
for domain organization and presence of intact active sites in
the domains. BecA was found to contain a loading module,
two additional complete modules, and one truncated module
and was thought to be responsible for synthesizing the C20-
C25 acyl side chain. As reported for several other type I modular
PKS clusters (Kuhstoss et al., 1996; Kakavas et al., 1997; Wal-
dron et al., 2001), the N-terminal domain of the loading module
resembles a ketoacyl synthase (KS) domain, but has a glutamine
residue instead of the usual conserved cysteine in the active site.
Such KSQ domains are thought to be responsible for chain initi-
ation by decarboxylating the starter unit selected by the AT
domain of the loading module (Bisang et al., 1999; Long et al.,
2002). The AT domain of the BecA loading module appears to
be specific for methylmalonyl-CoA with substrate-specific
motifs as described by Reeves et al. (2001). With decarboxyl-
ation by the KSQ domain, this leaves propionate as the first
unit to be incorporated in the biosynthesis of the side chain.
The AT domains of the extender modules 1, 2, and 3 are specific
for malonyl-CoA. The third module, however, is truncated after
the AT domain and lacks reductive and ACP domains.
The BE-14106 macrolactam ring is presumably synthesized
by the PKS enzymes BecB, BecD, BecE, BecF, and BecG.
BecB has an N-terminal ACP domain and in addition two
complete PKS modules. Presumably, the N-terminal ACP
domain represents a loading module for the initiation of the mac-
rolactam ring synthesis. Loadingmodules consisting of only ACP
domains have also been described in the biosynthesis of vicenis-
tatin (Ogasawara et al., 2004) and salinilactam (Udwary et al.,
2007). In both cases, the initiation of the biosynthesis might
involve the loading of an amino acid starter unit on the loading
module ACP domain. Upon loading of the aminoacyl starter
(see below), the biosynthesis of the BE-14106 macrolactam
ring is thought to proceed through modules 1–8. Besides the
extender modules 1 and 2 represented by BecB, BecD consti-
tutes modules 3 and 4, BecE module 5, BecF modules 6 and
7, and BecG module 8 as well as a C-terminal TE domain forlsevier Ltd All rights reserved
Chemistry & Biology





Protein Homologs (GenBank Accession
Numbers), % Positives/% Identity Putative Function
Homologs from vin
and slm Clusters
orf1 135 SCO7674 (NP_631713), 80/74 Putative secreted metal-binding protein
orf2 199 SCO7673 (NP_631712), 74/60 Putative lipoprotein
orf3 144 SGR_1584 (YP_001823096), 60/46 Hypothetical protein
becH 951 Orf30 (AAX98205), 52/36 LuxR-type transcriptional regulator Strop_2761
becA 5582 KijS1 (ACB46488), 62/49 Polyketide synthase type I
becI 362 SGR_5394 (YP_001826906), 60/47 Glycine oxidase/FAD-dependent
oxidoreductase
becC 694 LasAVI (CAQ64691), 57/45 Polyketide synthase type I
becU 187 SAV_606 (NP_821781), 57/47 Putative NRPS accessory protein
becB 3527 Strop_2768 (YP_001159588), 66/55 Polyketide synthase type I
becJ 532 Strop_2775 (YP_001159595), 73/58 AMP-dependent acyl-CoA
synthetase/ligase
VinN, Strop_2775
becK 323 VinK (BAD08368), 66/48 Acyltransferase VinK, Strop_2773
becS 78 VinL (BAD08369), 67/53 PCP VinL, Strop_2776
becL 505 Strop_2774 (YP_001159594), 71/58 NRPS adenylation domain VinM, Strop_2774
becM 198 Strop_2766 (YP_001159586), 65/48 TetR-type transcriptional regulator Strop_2766
becN 524 Strop_2765 (YP_001159585), 70/50 Major facilitator superfamily-type
efflux pump
Strop_2765
becO 411 Sare_1860 (YP_001536736), 55/38 P450 monooxygenase
becD 3372 SSAG_05828 (EDX26173), 66/55 Polyketide synthase type I
becP 313 VinJ (BAD08367), 79/65 Putative L-amino acid amidase/proline
iminopeptidase
VinJ, Strop_2777
becG 1986 Orf17 (AAX98192), 64/52 Polyketide synthase type I
becF 3377 LipPks2 (ABB05103), 64/53 Polyketide synthase type I
becE 1631 Orf16 (AAX98191), 61/50 Polyketide synthase type I
becT 95 Rv3281 (NP_217798), 59/40 Hypothetical protein, SimX2-like protein
becQ 257 SAV_953 (NP_822128), 67/48 Thioesterase type II Strop_2763
orf10 237 SGR_6303 (YP_001827815), 94/89 PlsC-type phospholipid/glycerol
acyltransferase
orf6 537 SAML1218 (CAJ90204), 85/75 Putative tripeptidylaminopeptidase
orf7 256 SGR_6300 (YP_001827812), 78/72 Putative urease accessory protein
orf8 231 SGR_6299 (YP_001827811), 92/87 Putative urease accessory protein
orf9 incomplete – Putative urease accessory protein
In addition to the closest homologs from GenBank, homologs from the vicenistatin (vin) and salinilactam (slm) clusters are also included.the release and lactamization of the reduced aminoacyl chain. All
AT domains in the BecB-G PKS system are specific for malonyl-
CoA except AT2 of BecB and AT6 of BecF, which are specific for
methylmalonyl-CoA. All modules (except the loading module)
contain both KR and DH domains, but the DH domain in BecE
appears to be inactive since the hydroxyl group at C-9 is intact.
The DH domain of BecE has an intact conserved active site motif
(H(X3)G(X4)P), but has a deletion in the C-terminal part of the
domain of about 40 amino acids compared to DH domains
from BecD, F, and G.
BecC is the second truncated PKS encoded by the gene
cluster and consists only of the KR and ACP domains. The
scheme described above involving the BecB-BecG enzymes
leaves no role for the BecC protein in the biosynthesis of the
macrolactam ring, thus suggesting its involvement in the biosyn-
thesis at an earlier step (see below).Chemistry & Biology 16, 1109Enzymes Presumably Involved in the Biosynthesis
of the Starter Unit
Wepropose that the BecI, BecJ, BecK, BecL, and BecS proteins
may be involved in the activation or modification of an aminoacyl
starter unit for the BE-14106 biosynthesis. Both BecL and BecJ
display homology to the LuxE-type adenylate-forming protein
superfamily, including acyl-CoA synthetases/ligases and NRPS.
BecL and BecJ showed the highest homology to the enzymes
Strop_2774 and Strop_2775, respectively, which were sug-
gested to be involved in the biosynthesis of salinilactam (Udwary
et al., 2007). The exact roles of Strop_2774 and Strop_2775 in
the biosynthesis of salinilactam have not been elucidated, but
they were presumed to be involved in the starter unit biosyn-
thesis (Udwary et al., 2007). BecL was also found to be homolo-
gous to other presumed or validated amino acid adenylation
enzymes, e.g., VinM from the biosynthesis of vicenistatin–1121, October 30, 2009 ª2009 Elsevier Ltd All rights reserved 1113
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Small-Ring Macrolactam with Acyl Side Chain(Ogasawara et al., 2004) and LnmQ from the leinamycin biosyn-
thesis (Cheng et al., 2003). For VinM, the exact role in the biosyn-
thesis has not been determined, although it was suggested that
the enzyme activates the starter unit 3-methylaspartate (Ogasa-
wara et al., 2004). LnmQ, on the other hand, was shown to
directly activate D-alanine as D-alaninyl-AMP and load it onto
an independent PCP domain, LnmP (Tang et al., 2007). An align-
ment of the protein sequences (Figure S2) of BecJ, BecL,
Strop_2774, Strop_2775, VinM, and LnmQ show that they all
contain the ten conserved core motifs of adenylating enzymes
(Marahiel et al., 1997). According to the mechanism suggested
by Reger et al. (2007), representatives of the LuxE superfamily
perform two half-reactions, namely adenylation of a substrate
and formation of a thioester using the adenylated substrate.
The latter reaction may involve both coenzyme A (yielding acyl-
CoA) or the pantheteine arm of the holo-PCP (yielding amino-
acyl-PCP). Amino acid residues necessary for the two half-reac-
tions are conserved in both BecL and BecJ, but these proteins
share only 28% identity, suggesting that they might use different
substrates, for example, amino acid and fatty acid. Phylogenetic
analysis of BecJ, BecL, and their closest homologs (Figure S3)
revealed that BecL (along with VinM and Strop_2775) clustered
with LnmQ, which was proven to be specific for an amino acid
substrate, while BecJ and Strop_2775 formed a separate clade.
Based on these considerations, we suggest that BecL is respon-
sible for activation of an amino acid, while BecJ uses a fatty acid-
like substrate, acting as an acyl-CoA ligase. A bioinformatics
analysis of BecL using NRPS predictor software (Rausch et al.,
2005) was performed to obtain a possible hint on the amino
acid starter for the BE-14106 biosynthesis. The analysis resulted
in prediction of BecL being specific for Gly = Ala = Val = Leu = Ile
with a specificity score 1.396. None of these amino acids could
be easily fitted into the biosynthesis of BE-14106, although
assumed specificity of BecL for glycine correlated with the pres-
ence of a glycine oxidase, BecI, shown to be essential for the
biosynthesis (see below).
BecS is homologous to LnmP, the PCP protein accepting acti-
vated D-alanine from the LnmQ adenylation domain in the leina-
mycin biosynthesis (Tang et al., 2007), and also shares homology
with VinL and Strop_2776 from the vicenistatin and salinilactam
biosynthesis pathways, respectively. VinL was assigned as an
aminoacyl carrier protein in the biosynthesis of vicenistatin, while
Strop_2776 is thought to be one of nine accessory proteins
involved in the starter unit synthesis of the salinilactam biosyn-
thesis. It is likely that BecS plays a similar role in the BE-14106
biosynthesis and the enzyme might serve the function of
a PCP domain for loading of an amino acid activated by BecL.
BecI represents a putative glycine oxidase/FAD-dependent
oxidoreductase and may be involved in the modification of the
aforementioned amino acid. BecI is homologous to several puta-
tive glycine oxidases from streptomycetes, some of which are
encoded in clusters of thiamin biosynthesis genes. An alignment
of protein sequences (Figure S4) for BecI, two glycine oxidases
from streptomycetes, and the glycine oxidase ThiO from the
thiamin biosynthesis pathway of Bacillus subtilis (Settembre
et al., 2003) showed that although the overall sequence similarity
between the streptomycete glycine oxidases and ThiO is not
high (25%–28%), most of the active site residues determined
for ThiO are conserved among all four enzymes.Moreover, larger1114 Chemistry & Biology 16, 1109–1121, October 30, 2009 ª2009areas surrounding the active site residues were also well
conserved, as were the FAD-binding residues, thus pointing to a
related function or mechanism for these proteins.
BecK represents a putative acyltransferase and showed the
highest homology to VinK from the vicenistatin biosynthesis.
VinK was suggested to be responsible for the transfer of the
amino acid-derived starter unit to an ACP domain (Ogasawara
et al., 2004). BecK was also homologous of Strop_2773, one of
nine accessory proteins thought to be involved in the starter
unit synthesis of the salinilactam biosynthesis. The substrate-
specific motifs of BecK, VinK, and Strop_2773 appear to be
rather special (see Table S2). Since the loading module of
BecB lacks an AT domain, it is possible that BecK functions as
an independent AT domain loading the starter unit onto the
ACP domain of the BecB loading module. The unique substrate
specificity motifs of BecKmost likely reflect an unusual structure
of the starter unit suggested for the BE-14106 biosynthesis (see
below).
Gene Inactivation Experiments
In order to verify the roles of certain genes in the biosynthesis of
BE-14106, a series of gene inactivation experiments was carried
out. The gene inactivation experiment using PCR-amplified frag-
ments from cosmid 2 and 3 (see above) involved the BecA
module 2 KS, AT, and DH domain-coding regions. The produc-
tion of BE-14106 was clearly affected in both mutants, although
they produced trace amounts of BE-14106. The low level of
production in the mutants may be a result of reversion to wild-
type for some cells and subsequent production during fermenta-
tion as only single crossover mutants were constructed. None-
theless, the experiment demonstrated an essential role for BecA
in the biosynthesis of BE-14106.
BecI, BecC, and BecP had questionable roles in the biosyn-
thesis of BE-14106, and the suggested role of BecO as a C-8
hydroxylase needed verification. Replacement vectors designed
to introduce deletions into these genes were constructed (see
Supplemental Experimental Procedures). Gene replacement
mutants with in-frame deletions were obtained for all genes
and verified by southern blot analyses (data not shown), and
the BE-14106 production was evaluated using LC-MS of fermen-
tation extracts. For the DbecO mutant, the expected mass cor-
responding to the stoichiometric formula (C27H37NO2) of the sug-
gested 8-deoxy BE-14106 was found with 1.0 ppm difference
from the theoretical mass (Figure S5). The role of BecO as a
P450 monooxygenase hydroxylating BE-14106 was thus con-
firmed. The C-8 carbon represents the only likely target of
BecO, since the hydroxyl group at the C-9 appears due to the
lack of the DH domain activity in the BecE PKS involved in the
biosynthesis of the macrolactam ring. LC-MS analyses of
fermentation extracts from the DbecI, DbecC, and DbecP
mutants all showed complete absence of BE-14106 production
and no putative BE-14106 analogs/precursors could be identi-
fied (data not shown).
Heterologous Expression and Enzyme Assays
of BecI and BecP
To shedmore light on the role ofBecI andBecP in the biosynthesis
of BE-14106, both enzymes were heterologously produced in
Escherichia coli as recombinant proteins with N-terminal andElsevier Ltd All rights reserved
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mental Experimental Procedures). All proteins were purified by
nickel affinity chromatography and their purity and molecular
weight were evaluated by SDS-PAGE (Figure S6). The apparent
observed molecular weights of the recombinant proteins were
close to those theoretically calculated (39.4 kDa for BecI and
35.6 kDa for BecP). The specificity of the purified proteins was
judged by enzyme assays with different substrates. The highest
activity was achieved with C-terminal His-tagged BecI and BecP
recombinant proteins. BecI-6xHis was tested with glycine, L- and
D-glutamine,L-andD-asparagine, andL-andD-lysine (FigureS7),
which were judged to be the most likely candidates for the bio-
synthesis of the starter unit based on the structure of BE-14106.
BecI-6xHis was able to utilize all substrates tested, but with
modest activity. The highest activity was obtained with glycine
(0.40 units/mg protein) and D-asparagine (0.21 units/mg protein).
The overall low activity level may be due to the presence of the
His tagor the need for anadditional protein partner.Another possi-
bility is that it may be necessary for the amino acid substrate to be
tethered to the PCP domain, BecS, for BecI to achieve its full
potential as a glycine/D-amino acid oxidase.
BecP-6xHis was initially only tested with L-proline-pNA (p-
nitroanilide). Sincegood activitywas obtainedwith this substrate,
the enzymeassaywas repeatedwith L-alanine-pNAandL-lysine-
pNA as negative controls to verify BecP’s assumed preference
for L-proline. Surprisingly, L-Ala-pNA turned out to be a much
better substrate for BecP. Considering the results from the BecI
enzyme assay, the BecP assay was repeated a second time
including also glycine-pNA as substrate. Gly-pNA turned out to
be a slightly better substrate than L-Pro-pNA, but still less
preferred than L-Ala-pNA. In an effort to investigate a potential
role for BecP in the resistance mechanism, the enzyme was also
incubated under the same assay conditions with purified BE-
14106 as substrate. Reaction mixtures with and without enzyme
were subjected to LC-MS for detection of any decomposition of
BE-14106, but no differencewas observed between the samples.
Feeding Studies Designed to Determine the Amino
Acids Used in the BE-14106 Biosynthesis
Based on the enzymatic activity of the recombinant BecI enzyme
assay, bioinformatics analysis of BecL, and the results of the gene
inactivation experiments it seemed likely that glycine might be
used as a starter for BE-14106 biosynthesis. However, at that
moment we could not exclude the possibility that other amino
acids, such as aspartate or glutamate, could be used as starters
in macrolactam biosynthesis (Ogasawara et al., 2004). To deter-
mine the starter amino acid, we first performed feeding experi-
ments where nine different unlabeled amino acids (glycine, D-
and L-alanine, D- and L-asparagine, D- and L-glutamine, D- and
L-aspartate, and D- and L-glutamate) were fed separately to the
BE-14106 producer cultivated on Silantes growth media with
15N- or 13C-labeled amino acids (see Experimental Procedures
fordetails). Toachievegoodgrowthof thecultures, twoalternative
nitrogen sources, ammonium sulfate or sodiumnitrate,were used
in these media. The feeding experiments were followed by LC-
DAD-TOF analyses of the BE-14106 molecules produced under
these conditions, which provided an estimate of incorporation of
either 14Nor 12C from the fedaminoacids into theBE-14106struc-
ture. In addition, production of BE-14106 under these conditionsChemistry & Biology 16, 1109–1was assessed. The volumetric yield of BE-14106 without fed
amino acids (control) was approximately 50 mg/liter in both
ammonium- and nitrate-supplemented BeSi medium. None of
the amino acids fed to the cultures had any significant effect on
the production of BE-14106. Isotope distribution plots were also
obtained in order to assess specificity of incorporation and to
rule out cases where amino acids were efficiently metabolized
(data not shown). Analysis of the data obtained clearly demon-
strated that the nitrogen atom from glycine was most efficiently
incorporated into the BE-14106 molecule on both ammonium-
and nitrate-containing media (Figure 3) compared to the other
amino acids tested, while the carbon atoms from glycine were
not incorporated to any extent. Apparently, fed amino acids
(except for L-aspartate), were more efficiently catabolized as
nitrogen and carbon sources on the medium containing nitrate,
as evidenced by the almost equal incorporation of their N and C
atoms into the BE-14106 molecule (Figure 3B).
To further confirm our findings, 15N- or 13C-labeled glycine,
L-asparagine, and L-glutamate (labeled D forms were not
commercially available) were fed to cultures grown on unlabeled
media, but under the same conditions as for the labeled media
described above. Approximately 50% incorporation of 15N
from glycine into the BE-14106 molecule was demonstrated in
these experiments when using either ammonium or nitrate as
nitrogen source, while no significant 13C incorporation could
be detected (Figure S8). Interestingly, up to 20% of the BE-
14106 molecules produced with labeled L-glutamate feeding
contained 15N from this amino acid. At the moment, we do not
have a plausible explanation for this observation.
Taken together, the results from both the ‘‘reverse’’ and the
‘‘direct’’ feeding experiments clearly suggest that glycine is the
preferred starter amino acid for the BE-14106 biosynthesis.
Intriguingly, carbon atoms from this amino acid were not incor-
porated into the BE-14106 molecule. This fact correlates well
with the assumed functions of BecA and BecC, which together
represent four complete PKS modules assembling a polyketide
chain from one propionate and three acetate units. Such a chain
could only be represented by the C25-C17 part of the BE-14106
molecule, leaving no space for incorporation of carbons from any
amino acid starter. Considering all the above, it seems likely that
glycine is used merely as a nitrogen atom donor in the biosyn-
thesis of the aminoacyl starter unit (see Discussion).
DISCUSSION
Based on the sequence analysis, gene inactivation experiments,
enzyme assays, and feeding studies, we propose amodel for the
BE-14106 biosynthesis in Streptomyces sp. DSM 21069 (Fig-
ure 4). The biosynthesis is thought to start with loading of meth-
ylmalonyl-CoA on the first ACP domain of BecA. Decarboxyl-
ation by the KSQ domain results in the propionyl starter unit
(C25-C23), which is extended with three acetate units by
modules 1 and 2 of BecA and the module 3 split between
BecA and BecC (C22-C17). Modules split between individual
PKS proteins have been described in several cases and they
appear to be functional (Duitman et al., 1999; Kopp et al.,
2005; Piel et al., 2004; Silakowski et al., 2001). The inactivation
of the becC gene led to complete abrogation of BE-14106
production, indicating an essential role for BecC in the121, October 30, 2009 ª2009 Elsevier Ltd All rights reserved 1115
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tide chain, glycine is assumed to be activated by the discrete
NRPS adenylation domain, BecL, followed by loading of the
glycine residue on the discrete PCP domain, BecS. Interaction
between BecS and the BecA/BecC complex may be mediated
by the putative NRPS accessory protein BecU, bringing the
glycine residue and the polyketide chain into proximity. BecU
homologs are encoded by genes situated close to NRPS- and
PKS-encoding genes in several genomes (e.g., Streptomyces
avermitilis MA-4680 and Microscilla marina ATCC 23134), indi-
cating that such enzymes may participate in interactions
between NRPS and PKS proteins. The feeding experiments
clearly established that glycine is the preferred amino acid
used for the biosynthesis of the aminoacyl starter, and the fact
that only the nitrogen atom from glycine is used suggests
a unique mechanism that must involve transfer of the nitrogen
to the acyl chain. There exist several examples where an amino-
acyl moiety is assembled by a PKS with the help of either an
embedded aminotransferase domain (mycosubtilin biosyn-
thesis; Aron et al., 2005) or through the extension of the acyl
chain with an amino acid by an NRPS module (FK520 biosyn-
thesis; Gatto et al., 2005). However, through the bioinformatics
analyses of the gene cluster described here and 15 kb DNA
regions flanking the cluster on each end (data not shown), we
were not able to identify any domains or proteins that could
possess either aminotransferase or condensation activity. The
Figure 3. Incorporation of Nitrogen and
Carbon Atoms from Unlabeled Glycine into
the BE-14106 Molecule in the Feeding
Experiments
Experiments were performed using the Silantes
growth media supplemented with ammonium
sulfate (A) or sodium nitrate (B).
importance of BecI for the biosynthesis
of BE-14106 and its specificity toward
glycine suggests that this enzyme is
involved in the transfer of the nitrogen
atom from glycine to the acyl chain
assembled by BecA-BecC PKS.
Although the exact mechanism
remains unclear at the moment and
requires further elucidation, the scheme
for the formation of the aminoacyl starter
presented in Figure 4A seems plausible.
We suggest that the acyl starter is assem-
bled from one propionate and three
acetate units by BecA-BecC PKS, and
then aminated at C-19. Bearing in mind
that BecI is homologous to glycine
oxidases and the chemistry of the first
half-reaction performed by this type of
enzymes (Scrutton, 2004), BecI is likely
to be involved in the amination using as
a substrate glycin activated by BecL
and tethered to BecS PCP. This is fol-
lowed by a reduction, possibly involving
KR domain of BecC, which leads to the
appearance of the C21-C22 double bond. The resulting aminoacyl
is likely to be released as a carboxylic acid via the action of the thi-
oesterase BecQ. In the next step, the putative acyl-CoA ligase,
BecJ, presumably activates the aminoacyl carboxylic acid to
produce its CoA thioester. The resulting aminoacyl-CoA is
assumed to be selected by the discrete acyltransferase BecK
and transferred to the loading module ACP domain of the BecB
PKS. The synthesis of the polyketide chain proceeds through
condensation of six malonyl-CoA and two methylmalonyl-CoA
units by BecB, BecD, BecE, BecF, and BecG. The TE domain of
BecG hydrolyses the thioester bond, catalyzes the cyclization of
the macrolactam ring, and releases the polyketide chain from the
PKS complex. As a final step in the biosynthesis, the 8-deoxy BE-
14106 is hydroxylated at C-8 by the P450 monooxygenase BecO.
The exact role of BecP, a putative iminopeptidase, remains
obscure, although, judging from the gene inactivation experi-
ment it is required for the BE-14106 biosynthesis. Supporting
the role of BecP as an iminopeptidase is the fact that BecP
was shown to cleave several different amino acid p-nitroaniline
substrates, displaying the highest activity with L-Ala-pNA fol-
lowed by Gly-pNA and L-Pro-pNA. It is thus tempting to specu-
late that BecP might be involved in the process of the aminoacyl
formation together with BecI. The presence of BecP homologs in
both the vicenistatin and salinilactam gene clusters (Table 2)
indicates that this enzyme’s function may be required for the
biosynthesis of these macrolactams as well.1116 Chemistry & Biology 16, 1109–1121, October 30, 2009 ª2009 Elsevier Ltd All rights reserved
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Cloning and analysis of the biosynthetic gene cluster for the
cytotoxic macrolactam BE-14106 provided new insights into
the biosynthesis of macrolactams, in particular those con-
taining acyl side chains. Based on the bioinformatics anal-
ysis and experimental data, involvement of two distinct
PKS systems, one functioning together with NRPS-related
enzymes in the assembly of a starter and another in the
synthesis of the ring, has been proposed. The synthesis of
the polyketide starter and themanner in which it is aminated
represents a newmechanism for generation of an aminoacyl
starter unit for macrolactam biosynthesis. Understanding of
the biosynthetic pathway, access to the genes, and demon-
strated possibility tomanipulate themopennewpossibilities
for modification of the BE-14106molecule and generation of
novel analogs with improved pharmacological properties.
EXPERIMENTAL PROCEDURES
Isolation of Strains from Sediments and Screening
for Antifungal Activity
Sediment samples were collected from different sites in the Trondheimsfjord
and used for isolation of marine actinomycetes as described by Bredholt
Figure 4. Proposed Model for the Biosyn-
thesis of BE-14106
(A) Synthesis and activation of the acyl amino acid
starter.
(B) Extension of the aminoacyl starter, cyclization,
and C-8 hydroxylation. Malonyl-CoA-specific AT
domains are shown in orange and methylma-
lonyl-CoA-specific AT domains are shown in blue.
et al. (2008). The strain designated Streptomyces
sp. DSM 21069 was isolated from a sediment
sample collected by scuba divers at 6 m depth
at position 6326N 1021E. The medium used for
isolation of this strain was IM8 (Bredholt et al.,
2008), supplemented with the antibiotics novobi-
ocin (20 mg/ml), cycloheximide (50 mg/ml), and
nystatin (75 mg/ml).
The collection of actinomycete strains obtained
from sediments was investigated for production of
antifungal activity using a set of different solidified
production media. For Streptomyces sp. DSM
21069, growth at 25C on medium PM2 (Bredholt
et al., 2008) for 7 days resulted in strong antifungal
activity. After the appropriate incubation time, the
medium was dried and then extracted with DMSO.
After filtration, the DMSO extracts were used as
samples in a robotic bioassay procedure with the
strains Candida albicans CCUG3943 and Candida
glabrata CCUG3942 as indicator organisms as
described by Jørgensen et al. (2009). The latter
strain has a high level of resistance against polyene
antibiotics, while theC. albicans strain is sensitive to
polyenes. The medium used in the bioassay was
AM19(B) (9.4g/literpeptone [Oxoid], 4.7g/liter yeast
extract [Oxoid], 2.4 g/liter beef extract [Difco], 10 g/
liter glucose [BDH], and distilled water).
Selected DMSO extracts displaying interesting
bioactivity were fractionated using an Agilent
1100 series HPLC system equipped with a diode array detector (DAD) and
a fraction collector. Each sample was fractionated in parallel using two
different types of LC columns: Agilent ZORBAX Eclipse XDB-C18, 5 mm,
4.6 3 150 mm, and Agilent SB-CN, 3.5 mm, 4.6 3 75 mm. For both types of
columns, a flow of 1 ml/min of a mixture of 0.005% formic acid in deionized
water and acetonitrile was used asmobile phase. In both cases the concentra-
tion of acetonitrile was kept at 40% the first minute, then increased linearly
from 40% to 95% during the next 9 min and kept at a concentration of 95%
for the rest of the run. The fraction collector was used to collect 12 fractions
of the eluent from 1 min until 13 min from injection.
The sampleswere dried in a vacuum centrifuge (Savant Speed-Vac) and dis-
solved in DMSO and the bioactivity of the fractions was determined in an agar
diffusion assay using the two yeast strains described above as indicator
organisms and AM19 as assay medium (equal to AM19B described above,
with 15 g/liter agar and 10 g/liter NaCl). The fractions with bioactivity were
analyzed using an Agilent 1100 series HPLC system connected to a DAD
and a time-of-flight (TOF) mass spectrometer. The same columns and buffers
were used in this analysis as described above for the fractionation step. Elec-
trospray ionization was performed in the negative (ESI-) mode. The DAD plots
were used to identify the approximate retention time of the bioactive
compounds in the fractionation runs and in the LC-MS-TOF analysis. Molec-
ular masses corresponding to significant peaks identified in bioactive samples
from parallel fractionations (C18 and CN columns) were compared and molec-
ular masses common to fractions from the C18 and CN columns were identi-
fied. These molecular masses (10 ppm window) were submitted to the online
version of the Dictionary of Natural Products (http://dnp.chemnetbase.com/)
in order to search for previously characterized compounds with bioactivity.Chemistry & Biology 16, 1109–1121, October 30, 2009 ª2009 Elsevier Ltd All rights reserved 1117
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For production of BE-14106 and its analog, deoxy-BE-14106, DSM 21069
strains were grown in 500 ml baffled shake flasks with 100 ml 0.33 BPS
medium (9 g/liter oatmeal, 1.5 g/liter malt extract, 0.9 g/liter yeast extract,
0.12 g/liter MgSO4x7H2O, 0.3 g/liter NaCl, 1.5 g/liter CaCO3, 9.0 g/liter soluble
starch, 11.0 g/liter MOPS, and 10.0 g/liter glucose [pH 7]). Each flask was sup-
plemented with 3 g of glass beads (3 mm) to increase the shearing force. The
flasks were incubated for 6 days at 25C (225 rpm, orbital movement, 2.5 cm
amplitude). The production cultureswere inoculatedwith 3 vol% from aprecul-
ture cultivated for 2 days at 25C (0.53 Tryptone Soya Broth supplemented
with 20 g/liter glucose in 500 ml baffled shake flasks). The incubation condi-
tions for the precultures were otherwise as described for the production
cultures.
Feeding Experiments
For the feeding studies with DSM 21069, precultures were grown in shake
flasks with glass beads in 0.53 TSB with glucose as described above. Ten
milliliters of each preculture was harvested by centrifugation and the cells
were washed with 40 ml BeDef medium, resuspended in 40 ml of the same,
and inoculated with 3 vol% in Silantes OD2 medium (Silantes) and incubated
for 1 day. The production and feedings were performed in deep well plates
with one 3 mm glass bead and 600 ml medium in each well at 25C, 80%
humidity, 800 rpm with a 3 mm amplitude for 6 days. The experiments were
performed in the BeSi medium consisting of 0.4 g/liter MgSO4x7H2O, 5.0 g/
liter CaCO3, 0.2 g/liter KH2PO4, and 536ml/liter SilantesOD2medium (Silantes
pr. No. 103002, 102202, and 100002). The Silantes addition to the media
represents a mix of 16 different amino acids at a total concentration of 0.26
mM. The minimal medium BeDef is a modified SMM medium (Takano et al.,
1992) without casaminoacids and PEG and with double amount of phosphate.
Both media were supplemented with 3 ml/liter trace mineral solution TMS1
(Borgos et al., 2006a), 10 g/liter glucose, and 0.34 g/liter (NH4)2SO4 or 0.44
g/liter NaNO3. A total of nine different unlabeled amino acids were tested in
this feeding experiment. The amino acids were supplemented two times
during cultivation (after 24 and 48 hr, 2.5 mM at each addition). Since many
D forms of amino acids are not available as 15N or 13C labeled, we chose to first
test a set of nine unlabeled amino acids (glycine, D- and L-alanine, D- and L-
asparagine, D- and L-glutamine, D- and L-aspartate, and D- and L-glutamate)
in media where all other carbon or nitrogen sources were either 15N or 13C
labeled.
In addition, feeding studies using three available 15N- and 13C-labeled amino
acids (glycine, L-glutamate, and L-aspartate) were performed using unlabeled
Silantes medium. The conditions were the same as for the experiments with
the labeled media. After cultivation, cultures were freeze-dried, extracted,
and analyzed on LC-DAD-TOF to determine how the isotopic distribution of
the mass spectra of BE-14106 was affected by the addition of different amino
acids.
Purification of BE-14106 and Deoxy-BE-14106
BE-14106 was purified in a two step purification process. Culture broth was
centrifuged and the pellet was freeze-dried. The dried pellet was extracted
with methanol (240 ml/g pellet) and filtered to remove any cell residues. BE-
14106 in the extract was precipitated with an equal amount of water. The
precipitated product was washed with water and thereafter freeze-dried.
Preparative LC-DAD-MS-guided purification was performed essentially as
described previously (Bruheim et al., 2004; Borgos et al., 2006b) but with
methanol (85%) instead of acetonitrile as the mobile phase organic constit-
uent.
LC-MS Assisted Determination of Production Yield
and Qualitative Analyses
Quantification of BE-141016 in fermentation broth was performed by extrac-
tion of the broth with an appropriate amount of methanol or DMSO followed
by LC-TOF or LC-qTOF analyses performed essentially as described above.
Concentrations of BE-14106 and deoxy-BE-14106 were determined by UV
peak absorption at 291 nm using BE-14106 purified by preparative HPLC as
a standard. Purity of BE-14106was determined by assuming thatmolar extinc-
tion coefficients in the spectral regions of interest were the same for BE-14106
and the contaminating derivatives.1118 Chemistry & Biology 16, 1109–1121, October 30, 2009 ª2009Confirmation of the Chemical Structure using NMR
Samples for NMR spectroscopy were prepared by dissolving the freeze-dried
compound in deuterated d6-DMSO to a concentration of about 1 mM. To
enable a direct comparison with NMR assignments reported previously, the
experimental conditions were analogous to those described earlier for BE-
14106 (Kojiri et al., 1992). All NMR experiments were recorded at 298 K on a
Bruker Avance 600 MHz spectrometer equipped with a 5 mm z-gradient TXI
(H/C/N) cryogenic probe. Proton and carbon chemical shifts were referenced
to TMS signal. To monitor the chemical structure of the investigated
compound both one dimensional 1H and two dimensional COSY and 1H-13C
HSQC spectra were recorded.
IC50 Determination
The antifungal activity of purified BE-14106 was determined in a robotic
bioassay procedure with the strains Candida albicans CCUG3943 and
Candida glabrata CCUG3942. Serial dilutions (six parallel wells) of the purified
compound was prepared in a 384 well plate and diluted samples were added
to assay plates containing medium M19B inoculated with the test strains.
Growth in the presence of various BE-14106 concentrations was compared
to growth in reference wells where only solvent (DMSO) was added, and the
concentration of BE-14106 resulting in 50% or more reduction in growth
was determined. Assay conditions were otherwise as described by Jørgensen
et al. (2009).
Cell Handling and Experimental Conditions for Cytotoxicity Testing
Jurkat-T human lymphoma cells (ATCC no. TIB-152) and NRK epithelial cells
(ATCC no. CRL-6509) were cultured in DMEM (EuroClon) supplemented with
10% heat-inactivated fetal bovine serum (Cambrex) in 40 ml flasks (Nunc) in
a humidified incubator (5% CO2, 37
C). For cytotoxicity testing, the cells
were seeded in 96 well tissue culture plates at 150,000 cells/ml (jurkat) or
50,000 cells/ml (NRK). The NRK cells were left in the incubator overnight to
attach to the substratum before experiments. The cells were exposed to
various concentrations of BE-14106 or vehicle for 22 hr before addition of
the cell mass (viability) reporter dye WST-1 (Roche Diagnostics). Plates were
read 2 hr after WST-1 addition and the cells were fixed in 2% formaldehyde
(pH 7.4) with the DNA-specific dyeHoechst 33342 (Polysciences Inc) to assess
apoptosis. Apoptotic surface and nuclear chromatin morphology were exam-
ined by phase contrast and UV microscopy (Zeiss axiover 35M) as described
before (Sandal et al., 2001, 2002).
Bacterial Strains, Media, and Growth Conditions
Bacterial strains and plasmids that were used in this study are listed in Table
S3. Streptomyces sp. DSM 21069 strains were maintained on ISP2 agar
medium (Difco), soy flour mannitol medium, and Mineral agar 1 Gause
(starch-soluble; 20 g/liter K2HPO4, 0.5 g/liter MgSO4, 0.5 g/liter KNO3, 1.0 g/
liter NaCl, 0.5 g/liter FeSO4, 0.01 g/liter agar, and 20.0 g/liter tap water). Liquid
cultures were grown in Tryptone Soya Broth (Oxoid). E. coli strains were grown
in Luriana-Bertani (LB) broth or on LB agar. For cloning, EZ cells were used for
vectors with blue-white selection, ER2925 was used when Dam/Dcm methyl-
ation-sensitive restriction enzymes were needed, and DH5a for general
cloning. M15 (pREP4) were used for the expression vectors pQE60/70. XL-
Blue MR was used for construction of the genomic library. ET12567
(pUZ8002) was used for intergeneric transfer of pSOK201-based constructs
to Streptomyces sp. DSM 21069. Antibiotics were supplemented to growth
media at the following concentrations: 100 or 150 mg/ml ampicillin, 50 or
100 mg/ml apramycin, 20 mg/ml chloramphenicol, 25 or 50 mg/ml kanamycin,
30 mg/ml nalidixic acid.
Cloning and sequencing of the BE-14106 gene cluster is described in detail
in the Supplemental Experimental Procedures.
Construction of Plasmids for Gene Inactivation Experiments
and Expression of Recombinant Proteins
Construction of plasmids used in this study is described in the Supplemental
Experimental Procedures and the plasmids are listed in Table S3. Recombi-
nant His-tagged proteins were purified following the procedure described by
Ortiz de Orue´ Lucana and Schrempf (2000), but with some modifications.
DH5a was used as a host for the expression of N-terminal His tag proteins
and M15 (pREP4) for the expression of C-terminal His tag proteins. CulturesElsevier Ltd All rights reserved
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ampicillin and 25 mg/ml kanamycin (pQE60/70) and induced at OD600 = 0.6 to
a final concentration of 1 mM IPTG. Cultures were harvested after 4 hr of
growth (succeeding the induction) and stored at 80C. Cells were resus-
pended in solution A (Ortiz de Orue´ Lucana and Schrempf, 2000) containing
10 mM imidazole and disrupted by sonication. Cellular debris was removed
by centrifugation (10.000 3 g, 25 min, 4C) and 0.5 ml Ni-NTA Agarose
(QIAGEN) (prewashed with solution A) was added to the cleared lysate. The
mixture was left rotating at 4C for 2 hr to allow proper binding of the recombi-
nant proteins before being loaded on the column (QIAGEN). The column was
washed twice with 10 ml solution A containing 20 mM imidazole. The recombi-
nant proteins were eluted with 43 0.5 ml solution A containing 300 mM imid-
azole. Glycerol was added to a final concentration of 15%and the eluates were
stored at 80C. Eluates, induced and preinduced culture samples, and
lysates were analyzed by SDS-PAGE and the protein concentration was deter-
mined by use of Nano-Drop (A280) with BSA as a standard.
Enzyme Assays for BecI and BecP
BecI
Enzyme assay was performed as described by the Sigma-Aldrich procedure
‘‘Enzymatic Assay of D-AMINO ACID OXIDASE APOENZYME’’ (http://www.
sigmaaldrich.com/etc/medialib/docs/Sigma/General_Information/d-amino_
acid_oxidase_apo_reactivation_assay.Par.0001.File.dat/). Unit definition for
the enzyme activity: one unit will oxidatively deaminate 1.0 mmol of substrate
per minute at pH 8.3 at 25C, in the presence of catalase.
BecP
Enzyme assay was performed as described by Uraji et al. (2007) with
a substrate concentration of 1 mM.
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